No Data
GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50(GIKLY.US) will release financial reports on November 7th.
$GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50(GIKLY.US)$ will release its financial report on November 7th, investors are advised to pay attention. How was the previous performance? $GRIFOLS SA SPON ADR EA REPR 1/2 ORD SHS EUR0.50(GIKLY.US)$ Q2 2024 revenue was 1.817907 billion euros, net income was 24.764 million euros, with an eps of 0.01 euros. 2023
GigaGen Awarded $135.2M U.S. Dept of Health Contract for Its Polyclonal Antibody Therapy
Grifols Class B Stock Falls as Brookfield Reportedly Seeks Lower Price
Grifols Receives Takeover Interest From Its Founding Family, Brookfield Fund; to Go Private
Grifols completed the sale of 20% of Shanghai RAAS Blood Products shares and reached a global strategy cooperation agreement with Haier Group.
With the announcement of today's completed transaction, Grifols and Haier will cooperate through Shanghai RAAS to enhance China's medical care system with synergies. Under the share purchase agreement, Grifols will sell 20% of Shanghai RAAS's shares to Haier Group for RMB 12.5 billion (approximately €1.6 billion). Grifols and Shanghai RAAS will extend their exclusive agency agreement for albumin for the next 10 years, and Shanghai RAAS may choose to extend it to 2044. All of Grifols' revenue will be used to fulfill its deleveraging commitments. Shanghai, June 18, 2024 /PRNewswire/-- Global medical and health companies and leaders.
6-K: Report of foreign private issuer (related to financial reporting)
No Data
No Data